1-Aethylcarbamoyl-3-(3-trifluormethylphenyl)-pyrrolidin | 29520-98-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-Aethylcarbamoyl-3-(3-trifluormethylphenyl)-pyrrolidin
• 英文别名: N-Ethyl-3-[m-(trifluoromethyl)phenyl]-1-pyrrolidinecarboxamide；N-ethyl-3-[3-(trifluoromethyl)phenyl]pyrrolidine-1-carboxamide
• CAS: 29520-98-7
• 化学式: C₁₄H₁₇F₃N₂O
• 分子量: 286.297
• InChiKey: ZMPKXPDJZJAPAU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] CRYSTALLINE FORM OF 5-AMINO-2,3-DIHYDROPHTHALAZINE-1,4-DIONE<br/>[FR] FORME CRISTALLINE DE 5-AMINO -2,3-DIHYDROPHTALAZINE-1,4-DIONE
  申请人：METRIOPHARM AG

  公开号：WO2017140430A1

  公开（公告）日：2017-08-24

  A new crystalline form of 5-amino-2,3-dihydro-1,4-phthalazinedione (luminol) is provided. Advantageous uses for this crystalline form as a detecting agent or as an agent for forensic purposes are disclosed, as well a pharmaceutical composition containing said crystalline form.

  提供了一种5-氨基-2,3-二氢-1,4-萘酮二酮（发光素）的新晶体形式。公开了该晶体形式作为检测试剂或法医目的试剂的优点用途，以及含有该晶体形式的药物组合物。
• USE OF 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE IN THE TREATMENT OF INFLAMMATORY AND/OR DEGENERATIVE DISORDERS OF THE TENDONS, LIGAMENTS OF THE JOINTS, ARTICULAR CAPSULES AND BURSAE
  申请人：MetrioPharm AG

  公开号：EP3248602A1

  公开（公告）日：2017-11-29

  The use of 5-amino-2,3-dihydro-1,4-phthalazinedione, its complexes, solvates, hydrates, crystalline polymorphs, tautomers, isomers, isotopically enriched forms, prodrugs or their pharmaceutically acceptable salts in the prophylaxis and/or treatment of inflammatory and/or degenerative disorders of the tendons, ligaments of the joints, articular capsules and bursae is disclosed, as well as suitable application forms. This medical use is particularly beneficial in poorly perfused tissues.

  本发明公开了 5-氨基-2,3-二氢-1,4-酞嗪二酮、其复合物、溶液剂、水合物、结晶多晶体、同分异构体、异构体、同位素富集形式、原药或其药学上可接受的盐在预防和/或治疗肌腱、关节韧带、关节囊和滑囊的炎症和/或退行性疾病中的用途，以及合适的应用形式。这种医疗用途对灌注不良的组织尤其有益。
• METHOD FOR SOLUBILIZING 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE
  申请人：MetrioPharm AG

  公开号：EP3511325A1

  公开（公告）日：2019-07-17

  The present invention relates to a method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione or salts thereof, to the solubilisate produced by this method and respective uses in pharmaceutical dosage forms. A phosphatidylcholine-based solubilization method is disclosed.

  本发明涉及一种增溶 5-氨基-2,3-二氢-1,4-酞嗪二酮或其盐类的方法，以及该方法产生的增溶剂和各自在药物剂型中的用途。公开了一种基于磷脂酰胆碱的增溶方法。
• USE OF 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE IN THE TREATMENT OF RARE CHRONIC INFLAMMATORY PULMONARY DISEASES
  申请人：MetrioPharm AG

  公开号：EP3858358A1

  公开（公告）日：2021-08-04

  The present invention relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione or one of its pharmaceutically acceptable salts in the treatment of rare chronic inflammatory pulmonary diseases. The invention in particular relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione sodium salt for said purposes.

  本发明涉及 5-氨基-2,3-二氢-1,4-酞嗪二酮或其药学上可接受的盐之一在治疗罕见慢性炎症性肺病中的用途。本发明尤其涉及 5-氨基-2,3-二氢-1,4-酞嗪二酮钠盐在上述用途中的使用。
• Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said form
  申请人：METRIOPHARM AG

  公开号：US10258620B2

  公开（公告）日：2019-04-16

  The invention relates to the provision of a new crystalline form for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium, the use of this form for medical purposes, methods for producing the crystalline form according to the invention, as well as pharmaceutical preparations comprising said form.

  本发明涉及 5-氨基-2,3-二氢酞嗪-1,4-二酮钠的一种新结晶形式、该形式在医疗方面的用途、根据本发明生产结晶形式的方法以及包含上述形式的药物制剂。